Related Experiment Video

Updated: Sep 20, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy

Jeffrey E Lancet1, Judith E Karp

  • 1James P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA. jeffrey_lancet@urmc.rochester.edu

Blood
|August 16, 2003
PubMed

Insights

Farnesyltransferase inhibitors (FTIs) show promise in treating blood cancers by blocking key proteins like Ras. Early trials indicate effectiveness, low toxicity, and clinical responses, paving the way for further research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Farnesyltransferase inhibitors (FTIs) target farnesylation of proteins like Ras, crucial for cell proliferation and survival.
  • Preclinical studies demonstrate FTI efficacy against diverse malignant phenotypes, suggesting potential in hematologic malignancies.
  • Hematologic malignancies often express targets such as Ras, MAPK, and AKT, which are dependent on farnesyl protein transferase (FTase) activity.

Purpose of the Study:

  • To assess the clinical applicability and efficacy of FTIs in hematologic malignancies.
  • To evaluate enzyme target inhibition, toxicity profiles, and clinical responses in Phase 1 trials.
  • To initiate Phase 2 trials for further validation and identification of downstream signaling targets.

Main Methods:

  • Phase 1 clinical trials to evaluate safety, tolerability, and preliminary efficacy of FTIs.
  • Enzyme activity assays to confirm target inhibition (FTase).
  • Initiation of Phase 2 trials in various hematologic malignancies to validate clinical activity.

Main Results:

  • Phase 1 trials demonstrated effective enzyme target inhibition by FTIs.
  • FTIs exhibited a favorable toxicity profile in early clinical assessments.
  • Some clinical responses were observed, supporting further investigation.

Conclusions:

  • FTIs are a promising therapeutic strategy for hematologic malignancies.
  • Ongoing Phase 2 trials aim to define optimal roles and combination strategies for FTIs.
  • Further research will elucidate downstream signaling pathways modulated by FTIs in cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...